SSG
BVS icon

Summit Securities Group’s Bioventus BVS Stock Holding History

Summit Securities Group’s Portfolio BVS Stock Details BVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,067
Closed -$7.06K – 1055
2025
Q2 		$7.06K Buy
+1,067
New +$7.57K ﹤0.01% 937
2025
Q1 		– Sell
-1,065
Closed -$11.2K – 824
2024
Q4 		$11.2K Buy
+1,065
New +$12.6K ﹤0.01% 439

Other funds holding BVS

EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
JIC
Juniper Investment Company New York $313M AUM 79.58% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
KLP
Kent Lake PR Anasco, Puerto Rico $198M AUM 5.21% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Summit Securities Group's BVS Position: Q3 2025 in Review

Summit Securities Group sold out of Bioventus (BVS) in Q3 2025, closing a stake of 1,067 shares — an estimated $7.06K sold.

Summit Securities Group first reported a position in BVS in Q4 2024 and held it in 2 quarters. The position peaked at $11.2K in Q4 2024. 135 funds tracked by Wall St. Rank hold BVS as of Q3 2025.

  • Summit Securities Group reported no remaining Bioventus position as of Q3 2025 after selling out during the quarter.
  • Summit Securities Group sold 1,067 Bioventus shares in Q3 2025, an estimated $7.06K.
  • Summit Securities Group first reported a position in Bioventus in Q4 2024 and held it in 2 quarters.
  • Summit Securities Group's Bioventus position peaked at $11.2K in Q4 2024.
  • 135 funds tracked by Wall St. Rank held Bioventus as of Q3 2025.

Based on Summit Securities Group's 13F filing for Q3 2025, filed 13 Nov 2025.